600276 恒瑞医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入31,629,41613.02%22,819,78521,275,27125,905,52627,734,599
减:营业总成本23,093,0989.93%18,214,15317,747,08421,792,96921,282,046
    其中:营业成本4,362,65613.37%3,525,2483,486,6393,741,7993,348,690
               财务费用(406,945)-28.95%(478,390)(470,867)(337,956)(181,744)
               资产减值损失(86,914)167.11%(107,217)(146,684)(13,861)(7,278)
公允价值变动收益173,57459.78%(58,257)76,50336,23316,497
投资收益(80,185)-1,973.76%(49,157)387,365213,434341,425
    其中:对联营企业和合营企业的投资收益(97,143)350.14%(72,696)(62,996)(6,940)--
营业利润8,990,00320.02%4,909,9054,111,9604,664,8167,007,072
利润总额8,707,62621.45%4,667,1103,968,4924,466,3096,895,480
减:所得税费用990,62318.97%389,289153,351(17,718)586,587
净利润7,717,00221.78%4,277,8213,815,1424,484,0276,308,893
减:非控股权益5,9471,171.82%(24,615)(91,233)(46,191)(19,490)
股东净利润7,711,05521.69%4,302,4363,906,3754,530,2186,328,383

市场价值指针
每股收益 (元) *1.19019.00%0.6800.6100.7100.990
每股派息 (元) *0.2000.00%0.2000.1600.1600.200
每股净资产 (元) *9.23229.37%6.3445.9295.4735.721
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容